Novartis (NVS) Drug Rydapt Receives EU Approval for Newly Diagnosed FLT3-mutated AML and Three Types of Advanced SM
Tweet Send to a Friend
Novartis (NYSE: NVS) today announced that the European Commission (EC) approved Rydapt® (midostaurin) for two indications in rare, hard-to-treat cancers ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
